SCHEMBL2653773

SCHEMBL2653773

Cc1cc2c(OCC(C)C)cc(C(=O)Nc3ncc(C(=O)O)s3)cc2o1

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GCK P35557 18/20 0.43
KCNH2 Q12809 3/20 0.40
MYC P01106 1/20 0.38
MAX P61244 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223615 0.90 GCK (0.41) GCKKCNH2MYCMAX
SCHEMBL2654282 0.82 SMN1; SMN2 (0.51) GCK
SCHEMBL2653534 0.80 GCK (0.58) GCKKCNH2
SCHEMBL2653597 0.79 MYC (0.41) GCKKCNH2MYCMAX
SCHEMBL2664716 0.78 GCK (0.54) GCK
SCHEMBL2655556 0.77 GCK (0.52) GCKKCNH2
SCHEMBL2653455 0.77 AR (0.41) GCKKCNH2MYCMAX
SCHEMBL2664722 0.74 GCK (0.63) GCK
SCHEMBL2664744 0.72 GCK (0.46) GCK
SCHEMBL22510115 0.70 SMN1; SMN2 (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578745-B1 BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF ASTRAZENECA AB (SE) 2007-11-14 EP claimed
US-20060058353-A1 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2006-03-16 US claimed
EP-1578745-A1 BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF Astrazeneca AB (SE) 2005-09-28 EP claimed
WO-2004046139-A1 BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF ASTRAZENECA AB (SE) 2004-06-03 WO claimed
US-7709505-B2 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-7709505-B2 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-7709505-B2 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2010-05-04 US disclosed
EP-1578745-B1 BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF ASTRAZENECA AB (SE) 2007-11-14 EP disclosed
US-20060058353-A1 Benzofuran derivatives, process for their preparation and intermediates thereof ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1578745-A1 BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF Astrazeneca AB (SE) 2005-09-28 EP disclosed
WO-2004046139-A1 BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF ASTRAZENECA AB (SE) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058353-A1 Benzofuran derivatives, process for their preparation and intermediates thereof GCK, PDK2, GCKR GCK 1/4885KCNH2 1214/4885MYC 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.